Open an account

Sinovac Biotech

SVA · NASDAQ

$6.47−$0.02 (−0.31%)TodayMarket closed ·
No price history for this range.

SVA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 1 analysts

Average $0.00 (−100.0% downside)

Low
$0.00
Now
$6.47
High
$0.00

Upgrades and downgrades

The latest rating actions, newest first

SVA analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 8, 2026MaintainsBuy

The case for and against

Updated Oct 21, 2026

Bull case

Sinovac Biotech is viewed positively because the combined platform appears to pair differentiated stem cell-derived islets with Cell Pouch delivery and in-house cGMP manufacturing, potentially creating a more integrated and scalable Type 1 diabetes replacement therapy. Encouraging SR-02 preclinical and in vivo data, including reduced blood glucose in diabetic immunocompromised animal models and grafts showing insulin- and glucagon-producing cells, support the biological rationale, while streamlined manufacturing and extended stability could improve yields and product durability. SR-03 adds longer-term upside through gene edits aimed at reducing immune rejection, with IND approval expected in 2H27, and the staged path toward initial recruitment in 4Q26 and initial data in 1H27 provides visible development milestones.

Bear case

Sinovac Biotech is viewed negatively because the excerpt points to strategic uncertainty, with a development program being discontinued and resources redirected toward a different platform, suggesting management is abandoning one path before it has proven durable value. The passage also highlights weak visibility on execution, noting failed or inconclusive clinical trials, the need to secure adequate funding, and the risk of dilutive capital raises, all of which can erode shareholder value. Even with some projected blockbuster potential, the very low 10% probability of success for both SR-02 and SR-03 and reliance on future financing and restructuring indicate a highly speculative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.